Novartis (NOVN.S), opens new tab expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will pay Monte Rosa Therapeutics (GLUE.O), opens new tab $150 million upfront payment for a global license to develop ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

The Swiss pharmaceutical firm now forecasts 2024 core operating income growth of a high-teens percentage, compared with its previous target of a mid- to high-teens percentage. Novartis now ...

Novartis raised its 2024 earnings guidance for the third time this year - Copyright AFP/File SEBASTIEN BOZON Novartis raised its 2024 earnings guidance for the third ...

Switzerland-based Novartis has an Earnings ESP of +1.51% and carries a Zacks Rank #2. The Zacks Consensus Estimate for the third quarter is pegged at earnings of $1.94 per share. Novartis is set ...

Novartis AG’s NVS Fabhalta (iptacopan). Also Read: Apellis Pharmaceuticals’ Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases. However, Empaveli has a ...

Basel, October 18, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

"Building on the longstanding experience of Novartis in nephrology and our first rare kidney disease approval in IgA nephropathy earlier this year, these results in C3G show continued advancement ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...